Reply To: Bond Traders Weekly Outlook: The Wild Ride of 2023 Moves Onto 2024

#69450
Truman
Participant

Iovance Biotherapeutics (IOVA 5.97, -2.92, -32.9%):
Announces clinical program update for LN-145 in non-small cell lung cancer; The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023